Cargando…

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease

Graft-versus-host disease (GVHD) is a serious and deadly complication of patients, who undergo hematopoietic stem cell transplantation (HSCT). Despite prophylactic treatment with immunosuppressive agents, 20–80% of recipients develop acute GVHD after HSCT. And the incidence rates of chronic GVHD ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lingling, Yu, Jianhua, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964137/
https://www.ncbi.nlm.nih.gov/pubmed/29868032
http://dx.doi.org/10.3389/fimmu.2018.01087